JP4892833B2 - Fat absorption inhibitor - Google Patents

Fat absorption inhibitor Download PDF

Info

Publication number
JP4892833B2
JP4892833B2 JP2004365631A JP2004365631A JP4892833B2 JP 4892833 B2 JP4892833 B2 JP 4892833B2 JP 2004365631 A JP2004365631 A JP 2004365631A JP 2004365631 A JP2004365631 A JP 2004365631A JP 4892833 B2 JP4892833 B2 JP 4892833B2
Authority
JP
Japan
Prior art keywords
extract
fat absorption
action
fat
bald
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004365631A
Other languages
Japanese (ja)
Other versions
JP2006169181A (en
Inventor
朱 印南
啓介 今田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP2004365631A priority Critical patent/JP4892833B2/en
Publication of JP2006169181A publication Critical patent/JP2006169181A/en
Application granted granted Critical
Publication of JP4892833B2 publication Critical patent/JP4892833B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

本発明は肥満および高トリグリセリド血症を予防および改善するとともに、肥満に起因する糖尿病、高脂血症、高血圧症、動脈硬化といった疾患の予防に有効な天然物由来の脂肪吸収抑制剤に関する。   The present invention relates to a fat absorption inhibitor derived from a natural product that is effective for preventing and improving obesity and hypertriglyceridemia, and for preventing diseases such as diabetes, hyperlipidemia, hypertension and arteriosclerosis caused by obesity.

従来、日本人の食事は炭水化物が中心であったが、近年はファーストフードを始めとした欧米型の食事が普及し、脂肪の摂取量が多くなってきている。平成14年度の国民1人1日当たりの栄養素等摂取量を見ると、エネルギー摂取量に占める脂質エネルギーの割合が、20〜40歳代で適正比率の上限である25%を上回っている状況である(非特許文献1)。   Traditionally, Japanese meals have been mainly carbohydrates, but in recent years, Western-style meals such as fast food have become widespread and fat intake has increased. Looking at the nutrient intake per person per day in 2002, the ratio of lipid energy to energy intake is in excess of 25%, the upper limit of the appropriate ratio in the 20-40s. (Non-patent document 1).

脂肪の過剰摂取は肥満および血清高トリグリセリド血症の原因である。また、肥満ではインスリン抵抗性が惹起され、糖尿病、高脂血症、高血圧症、動脈硬化性疾患の発症率が高いことが知られている。このことから、食物中の脂肪の吸収を抑制する薬剤は、肥満や血清高トリグリセリド血症の予防または改善に有効であるにとどまらず、肥満に起因する糖尿病、高脂血症、高血圧症、動脈硬化性疾患といった疾患の発症を予防し、生活の質の向上に寄与すると考えられる。   Fat overdose is the cause of obesity and serum hypertriglyceridemia. In obesity, insulin resistance is induced, and it is known that the incidence of diabetes, hyperlipidemia, hypertension, and arteriosclerotic diseases is high. Therefore, drugs that suppress the absorption of fat in foods are not only effective in preventing or improving obesity and serum hypertriglyceridemia, but also in diabetes, hyperlipidemia, hypertension, arteries caused by obesity. It is thought to contribute to improving the quality of life by preventing the onset of diseases such as sclerotic diseases.

実際、欧米において発売されている医療用医薬品のオルリスタットは食事中の脂肪吸収を抑制し、抗肥満作用および血清高トリグリセリド血症改善作用を示すことが知られている。しかしながらオルリスタットは胃腸障害や脂肪便等の副作用の報告も多いことから、作用が穏やかで、長期間にわたって摂取しても安全性の高い、天然物由来の脂肪吸収抑制剤が求められている。   In fact, orlistat, an ethical drug marketed in Europe and the United States, is known to suppress fat absorption during meals and to exhibit an anti-obesity effect and an effect of improving serum hypertriglyceridemia. However, since orlistat has many reports of side effects such as gastrointestinal disorders and fatty stool, there is a demand for a natural product-derived fat absorption inhibitor that has a mild action and is highly safe even when ingested over a long period of time.

食物中の脂肪の大半を占めるトリグリセリドは、胃および膵臓から分泌されるリパーゼによって脂肪酸とモノグリセリドに分解されて、小腸において吸収される。よって脂肪の吸収を抑制するためには、リパーゼの阻害、または小腸での脂肪酸およびモノグリセリド吸収の阻害という2つの機序が考えられる。現在のところ、実際に脂肪の吸収を抑制する作用が認められているのはリパーゼ阻害剤であり、前述のオルリスタットを始めとした多くのリパーゼ阻害剤において、その作用が報告されている。   Triglycerides, which account for most of the fat in food, are broken down into fatty acids and monoglycerides by lipases secreted from the stomach and pancreas and absorbed in the small intestine. Therefore, in order to suppress the absorption of fat, two mechanisms of inhibition of lipase or inhibition of fatty acid and monoglyceride absorption in the small intestine can be considered. At present, it is lipase inhibitors that actually have an action of suppressing fat absorption, and the action has been reported in many lipase inhibitors including the aforementioned orlistat.

従来、脂肪の吸収を抑制する天然物由来の素材としては、脱脂カカオマス(特許文献1)が知られている。また、リパーゼ阻害作用を示す天然物としては、ドッカツ、リョウキョウ、ビンロウシ、ヨウバイヒ、サンペンズおよびケツメイシ(特許文献2)、レモングラス、オールスパイス、シナモン又はクローブ(特許文献3)、アルファルファ抽出物、苦丁茶抽出物、金銀花抽出物、ペパーミント抽出物、チョウジ抽出物、セイヨウキズタ抽出物、オリーブ抽出物およびラフマ茶抽出物(特許文献4)、ウワウルシ、西洋サクラソウ、ボダイジュ、アスパラガス、イチョウ、ウアナルポマチョ、オオアワダチソウ、リンデン、カツアーバ、ユーカリ、コウキ、カスカラサグラダ、オノニス、ムユウジュ、セネガの植物及びローヤルゼリー(特許文献5)などが開示されている。   Conventionally, defatted cocoa mass (Patent Document 1) is known as a material derived from a natural product that suppresses fat absorption. Examples of natural products exhibiting a lipase inhibitory action include Dokatsu, Ryoko, Betel, Beehi, Sunpens and Ketsumeishi (Patent Document 2), Lemongrass, Allspice, Cinnamon or Clove (Patent Document 3), Alfalfa extract, Bitter Dingcha extract, Gold and silver flower extract, Peppermint extract, Clove extract, Kizuta extract, Olive extract and Luffa tea extract (Patent Document 4), Walnut, Western primrose, Bodaiju, Asparagus, Ginkgo, Huanalpomacho Plant, royal jelly (Patent Document 5), and the like are disclosed.

ハクトウオウ(白頭翁)はキンポウゲ科の植物ヒロハオキナグサ(Pulsatilla chinensis)、の根を乾燥したものである。薬理作用としては強心作用、末梢血管拡張作用、内臓神経系支配の血管収縮作用、抗アメーバ原虫作用、抗膣トリコモナス作用、抗菌作用が知られている。漢方では清熱、解毒を目的に使用されている。   Bald eagle is a dried root of the plant of the family Ranunculaceae, Pulsatilla chinensis. As pharmacological actions, cardiotonic action, peripheral vasodilatory action, vasoconstriction action governed by visceral nervous system, anti-amoeboid protozoa action, anti-vaginal trichomonas action, and antibacterial action are known. In Kampo, it is used for cleansing and detoxification purposes.

ミツモウカ(密蒙花)はフジウツギ科の植物ワタフジウツギ(Buddleia officinalis Maxim)の蕾を花が開かないうちに採取し、乾燥したものである。薬理作用に関する報告はほとんどないが、解熱、消炎、眼病治療の用途で使用されている。   The honey beetle (Mitsumonka) is a flower of Buddleia officinalis Maxim, which is collected before the flower opens, and dried. Although there are few reports on pharmacological effects, it is used for antipyretic, anti-inflammatory and ophthalmic treatments.

カイトウヒ(海桐皮)はマメ科のデイゴ(Erythrina indica L. = E. variegata L. var. orientalis (L.) Merr.)の樹皮を乾燥したものである。また、ミカン科のカラスザンショウ(Zanthoxylum ailanthoides Sieb. Et zucc.)、ウコギ科のハリギリ(Kalopanax pictus(thumb.) Nakagi)およびパンヤ科のキワタノキ(Bombax malabaricum DC.)も海桐皮と称されている。薬理作用としては皮膚真菌や黄色ブドウ球菌に対する抑制作用が報告されている。薬剤としては関節リウマチなどの鎮痛剤や、皮膚疥癬や歯痛の用途で使用されている。   Kite spruce (sea paulownia bark) is a dried bark of the leguminous deigo (Erythrina indica L. = E. variegata L. var. Orientalis (L.) Merr.). The citrus family Zanthoxylum ailanthoides Sieb. Et zucc., The scallop family Kalopanax pictus (thumb.) Nakagi, and the Panya family Bombax malabaricum DC. Yes. As a pharmacological action, an inhibitory action against skin fungi and Staphylococcus aureus has been reported. As a drug, it is used for analgesics such as rheumatoid arthritis, skin scabies and toothache.

ハクシジン(柏子仁)はヒノキ科の植物コノテガシワ(Thuja orientalis L.= Biota orientalis (L)ENDL.)の種子より皮を除いて得た種仁を乾燥したものである。薬理作用に関する報告はほとんどないものの、滋養、強壮、不眠、便秘の用途で使用されている。なお、コノテガシワの枝および葉はソクハクヨウ(側柏葉)として知られているが、主成分、用途ともハクシジンとは異なるものである。   Hakushijin is a dried seed of seeds obtained by removing the skin from the seeds of the cypress family Thuja orientalis L. = Biota orientalis (L) ENDL. Although there are few reports on pharmacological effects, it is used for nourishment, tonic, insomnia, and constipation. Note that the branches and leaves of Konotegasiwa are known as Sakuhakuyo (acupuncture leaves), but their main components and uses are different from those of Hakushidin.

トウガシ(冬瓜子)はウリ科のトウガ=カモウリ(Benincasa cerifera Savi = B. hispida (Thumb.) Cogn.)の成熟種子を乾燥したものである。薬理作用に関する報告はほとんどないが、鎮咳、去痰、排膿、消炎性利尿薬として、内臓の化膿症(内癰)・熱痰による咳嗽に補助薬として用いられている(非特許文献2、3)。なお、トウガの果実部分はトウガ(冬瓜)として知られており、ダイエット食品として広く知られているが、その種子であるトウガシとは主成分、用途とも異なるものである。   Capsicum (winter coconut) is a dried mature seed of Benincasa cerifera Savi = B. hispida (Thumb. Cogn.). Although there are almost no reports on pharmacological action, it is used as an auxiliary agent for cough due to visceral suppuration (internal hemorrhoids) or fever as an antitussive, expectorant, drainage, anti-inflammatory diuretic (Non-patent Documents 2 and 3) ). In addition, although the fruit part of a chili pepper is known as a chili (winter basket) and is widely known as a diet food, the chili pepper which is the seed is different from a main component and a use.

特開平6-321796JP-A-6-321796 特開平5-255100JP 5-255100 A 特開2001-120237JP2001-120237 特開2003-26585JP2003-26585 特開2003-192605JP2003-192605 国民栄養の現状/平成14年厚生労働省国民栄養調査結果、健康・栄養情報研究会編Current Status of National Nutrition / 2002 National Nutrition Survey, Ministry of Health, Labor and Welfare, Health and Nutrition Information Study Group 難波恒夫著、和漢薬百科図鑑[I]、保育社、p.57-58、p.286-287、p.219-220Namba Tsuneo, Encyclopedia of Japanese and Chinese Medicine [I], Childcare, p.57-58, p.286-287, p.219-220 難波恒夫著、和漢薬百科図鑑[II]、保育社、p.112-113、p.154-156Namba Tsuneo, Encyclopedia of Japanese and Chinese Medicine [II], Yoikusha, p.112-113, p.154-156

本発明の目的は、天然物由来の脂肪吸収抑制剤を提供することにある。   An object of the present invention is to provide a fat absorption inhibitor derived from a natural product.

本発明者らは上記課題を解決するために鋭意検討を行った結果、ある種の生薬またはそのエキスが優れた脂肪吸収抑制作用を有するとともに、その作用がリパーゼ阻害作用に起因することを見出し、本発明を完成した。   As a result of intensive studies to solve the above problems, the present inventors have found that certain herbal medicines or extracts thereof have an excellent fat absorption inhibitory action, and that the action is attributable to a lipase inhibitory action, The present invention has been completed.

すなわち本発明は、
1)ハクトウオウ、ミツモウカ、カイトウヒ、ハクシジンおよびトウガシからなる群から選ばれる1種または2種以上を配合することを特徴とする脂肪吸収抑制剤。
2)ハクトウオウ、ミツモウカ、カイトウヒ、ハクシジンおよびトウガシからなる群から選ばれる1種または2種以上を配合することを特徴とするリパーゼ阻害剤。
3)ハクトウオウ、ミツモウカ、カイトウヒ、ハクシジンおよびトウガシからなる群から選ばれる1種または2種以上を配合することを特徴とする肥満の予防または改善剤。
4)ハクトウオウ、ミツモウカ、カイトウヒ、ハクシジンおよびトウガシからなる群から選ばれる1種または2種以上を配合することを特徴とする血清高トリグリセリド血症の予防または改善剤。
である。
That is, the present invention
1) The fat absorption inhibitor characterized by mix | blending 1 type (s) or 2 or more types chosen from the group which consists of a bald eagle, a honey beetle, a spruce, a cabbage, and a red pepper.
2) A lipase inhibitor comprising one or more selected from the group consisting of bald owl, honey beetle, silk spruce, hakushidin and chili.
3) A prophylactic or improving agent for obesity, comprising one or more selected from the group consisting of bald owl, honey beetle, silk spruce, hakushidin and chili.
4) A preventive or ameliorating agent for serum hypertriglyceridemia, comprising one or more selected from the group consisting of bald eagle, honey beetle, spruce spruce, Chinese cabbage, and red pepper.
It is.

本発明は脂質の吸収阻害作用を有することから、肥満、血清高トリグリセリド血症の予防または改善に有効であるとともに、肥満に起因する糖尿病、高脂血症、高血圧症、動脈硬化といった疾患の予防にも有効である。   Since the present invention has an action of inhibiting lipid absorption, it is effective in preventing or improving obesity and serum hypertriglyceridemia, and preventing diseases such as diabetes, hyperlipidemia, hypertension and arteriosclerosis caused by obesity. Also effective.

本発明に係るハクトウオウ、ミツモウカ、カイトウヒ、ハクシジンおよびトウガシはそのまま生薬末として、また、水、極性溶媒、それらの混合溶媒などで抽出したエキスとして使用することができるが、水とアルコールを等量混合した溶媒を用いて抽出したエキスが好ましい。また、エキスは乾燥エキス、流エキスなどを用いることもできる。   The bald eagle, honey beetle, silk spruce, cabbage and hot pepper according to the present invention can be used as a crude drug powder, or as an extract extracted with water, a polar solvent, a mixed solvent thereof or the like, but water and alcohol are mixed in equal amounts. An extract extracted with the above solvent is preferred. Moreover, a dry extract, a flow extract, etc. can also be used for an extract.

本発明で用いる生薬成分は単品または混合して用いることができる。   The herbal medicine components used in the present invention can be used alone or in combination.

本発明の脂肪吸収抑制剤の投与量は、年齢、性別などを考慮して適宜増減できるが、通常成人で1日あたり、原生薬換算量として100mg〜50gの範囲で用いることができ、好ましくは、500mg〜5gである。   The dosage of the fat absorption inhibitor of the present invention can be appropriately increased or decreased in consideration of age, gender, etc., but can be used in the range of 100 mg to 50 g as an active ingredient equivalent per day for normal adults, preferably 500 mg to 5 g.

本発明は、発明の効果を損なわない質的および量的範囲で、ビタミン、キサンチン誘導体、アミノ酸、賦形剤、pH調製剤、清涼化剤、懸濁化剤、消泡剤、粘稠剤、溶解補助剤、崩壊剤、結合剤、滑沢剤、抗酸化剤、コーティング剤、着色剤、矯味矯臭剤、界面活性剤、可塑剤、香料などを配合して、常法により、液剤、錠剤、顆粒剤、散剤、カプセル剤、ドライシロップ剤、チュアブル錠、経粘膜剤などの経口または非経口製剤とすることができる。   The present invention is a qualitative and quantitative range that does not impair the effects of the invention, vitamins, xanthine derivatives, amino acids, excipients, pH adjusting agents, cooling agents, suspending agents, antifoaming agents, viscous agents, Solubilizing agents, disintegrating agents, binders, lubricants, antioxidants, coating agents, coloring agents, flavoring agents, surfactants, plasticizers, fragrances, etc. are blended, and liquids, tablets, Oral or parenteral preparations such as granules, powders, capsules, dry syrups, chewable tablets and transmucosal agents can be used.

本発明の生薬成分は優れた脂肪吸収阻害作用、リパーゼ阻害作用を有することが明らかになった。   It was revealed that the herbal medicine component of the present invention has an excellent fat absorption inhibitory action and lipase inhibitory action.

以下に実施例および試験例をあげ、本発明を具体的に説明する。   The present invention will be specifically described below with reference to examples and test examples.

ハクトウオウを細切後、10倍量の50%エタノールを加え、約80℃で加熱抽出し、濾過後減圧下でエタノールを留去し、さらに、濃縮を行うことによりエキスを得た。   After chopping the bald eagle, 10 times the amount of 50% ethanol was added, and the mixture was extracted by heating at about 80 ° C. After filtration, the ethanol was distilled off under reduced pressure, and further concentrated to obtain an extract.

なお、ミツモウカ、カイトウヒ、ハクシジンおよびトウガシについても同様の抽出法で抽出しエキスを製造した。   In addition, the extract was manufactured by extracting with the same extraction method also about mitsumouka, a spruce, a cabbage, and a red pepper.

試験例1(ラットにおける脂肪吸収抑制作用の測定)
SDラット(雄性)を1群7匹で2群に分け、試験前日より16-20時間の絶食を行った。そのうち1群には生薬エキスを10mL/kgの用量で経口投与し、その直後に3H標識トリオレインを1mL/匹の用量で経口投与した。別の1群は対照群とし、生薬エキスの代わりに精製水10mL/kgを経口投与し、その直後に3H標識トリオレインを経口投与した。なお、生薬エキスは、エキスとして1g/10mLとなるように精製水で希釈したものを用いた。3H標識トリオレインは、トリオレインとして0.25nmol(放射活性として486.55kBq)をガラスチューブに分注し、窒素ガスで溶媒を蒸発させ、0.5% Tween-80溶液1mLを加えて10分間超音波処理することによって分散させたものを用いた。3H標識トリオレインの投与から30、60、90、120分後に尾静脈より無麻酔下で採血を行い、ヘパリン入りのチューブに血液を回収した。遠心分離によって血漿を分離し、そのうち50μLをシンチレータ溶液10mLとよく混ぜ合わせ、液体シンチレーションカウンターを用いて放射活性を測定した。
Test Example 1 (Measurement of fat absorption inhibitory effect in rats)
SD rats (male) were divided into 2 groups with 7 rats per group and fasted for 16-20 hours from the day before the test. In one group, herbal extract was orally administered at a dose of 10 mL / kg, and immediately after that, 3 H-labeled triolein was orally administered at a dose of 1 mL / animal. Another group was used as a control group, and 10 mL / kg of purified water was orally administered instead of the herbal extract, and immediately after that, 3 H-labeled triolein was orally administered. In addition, the crude drug extract used what was diluted with purified water so that it might become 1g / 10mL as an extract. For 3 H-labeled triolein, 0.25 nmol as triolein (486.55 kBq as radioactivity) is dispensed into a glass tube, the solvent is evaporated with nitrogen gas, and 1 mL of 0.5% Tween-80 solution is added and sonicated for 10 minutes. What was dispersed by using was used. 30, 60, 90, and 120 minutes after administration of 3 H-labeled triolein, blood was collected from the tail vein without anesthesia, and the blood was collected in a tube containing heparin. Plasma was separated by centrifugation, 50 μL of which was mixed well with 10 mL of scintillator solution, and radioactivity was measured using a liquid scintillation counter.

対照群および生薬エキス投与群の血漿50μLの放射活性の経時変化を図1に示した。さらに、血中濃度曲線下面積(AUC)を算出し、対照群のAUCに対する生薬エキス投与群のAUCの減少率を脂肪吸収阻害率(%)とし、表1に示した。   The time course of 50 μL of plasma radioactivity in the control group and the crude drug extract administration group is shown in FIG. Furthermore, the area under the blood concentration curve (AUC) was calculated, and the decrease rate of AUC in the herbal extract extract group relative to the AUC in the control group was defined as the fat absorption inhibition rate (%) and shown in Table 1.

Figure 0004892833
Figure 0004892833

図1、表1から明らかなように、生薬エキス投与群には脂肪吸収抑制作用が認められた。   As is clear from FIG. 1 and Table 1, a fat absorption inhibitory effect was observed in the herbal extract extract group.

試験例2(リパーゼ阻害作用の測定)
基質溶液(0.2 mM 4-methylumbelliferyl oleate)50μLに実施例1で得た各生薬エキス(2.5% DMSOで溶解)25μLおよび酵素溶液(100U/mL pancreatic lipase,TypeVI-S from porcine pancreas)25μLを添加した。37℃で15分間反応させた後、0.1M塩酸150μLおよび0.1Mクエン酸ナトリウム25μLを加え、励起波長320nm、蛍光波長450 nmにおける蛍光吸収を測定した。なお、各生薬エキスは最終濃度として12.5、25、50および100μg/mLの各濃度となるように添加した。
Test Example 2 (Measurement of lipase inhibitory action)
25 μL of each herbal extract obtained in Example 1 (dissolved in 2.5% DMSO) and 25 μL of enzyme solution (100 U / mL pancreatic lipase, Type VI-S from porcine pancreas) were added to 50 μL of a substrate solution (0.2 mM 4-methylumbelliferyl oleate). . After reacting at 37 ° C. for 15 minutes, 150 μL of 0.1M hydrochloric acid and 25 μL of 0.1M sodium citrate were added, and fluorescence absorption at an excitation wavelength of 320 nm and a fluorescence wavelength of 450 nm was measured. Each crude drug extract was added so as to have final concentrations of 12.5, 25, 50, and 100 μg / mL.

生薬エキス無添加群を100%としたときの生薬エキス配合群の蛍光をリパーゼ阻害率(%)として表した結果を図2に、50%活性阻害濃度を表2に示した。   The results of expressing the fluorescence of the herbal extract extract group as the lipase inhibition rate (%) when the crude drug extract-free group is 100% are shown in FIG. 2, and the 50% activity inhibition concentration is shown in Table 2.

Figure 0004892833
Figure 0004892833

図2、表2から明らかなように、ラットにおける脂肪吸収を抑制した生薬エキス投与群には、リパーゼの阻害作用が認められた。   As apparent from FIG. 2 and Table 2, the lipase inhibitory action was observed in the herbal extract administration group that suppressed fat absorption in rats.

本発明の生薬は優れた脂肪吸収抑制作用を有することから、肥満、血清高トリグリセリド血症など脂肪の蓄積に由来する疾患、さらに肥満に起因する糖尿病、高脂血症、高血圧症、動脈硬化といった疾患の治療または予防用の医薬品、食品、機能性食品などに利用可能である。   Since the herbal medicine of the present invention has an excellent fat absorption inhibitory effect, diseases such as obesity, serum hypertriglyceridemia, and other diseases derived from accumulation of fat, diabetes caused by obesity, hyperlipidemia, hypertension, arteriosclerosis, etc. It can be used for pharmaceuticals, foods, functional foods, etc. for treatment or prevention of diseases.

本発明の各生薬エキスについての脂肪吸収抑制作用を示した図であり、各縦軸にラット血漿50μLの放射活性を、各横軸に3H標識Trioleinの投与から経過した時間を示した。A view showing the fat absorption inhibiting action of the herbal extract of the present invention, the radioactivity of rat plasma 50μL each vertical axis shows the elapsed time from administration of 3 H-labeled Triolein each horizontal axis. 本発明の各生薬エキスについてのリパーゼ活性阻害率を示した図であり、各縦軸に阻害率、各横軸にエキス濃度を示した。It is the figure which showed the lipase activity inhibition rate about each crude drug extract of this invention, and showed the inhibition rate on each vertical axis | shaft, and the extract density | concentration on each horizontal axis.

Claims (4)

キンポウゲ科の植物ヒロハオキナグサ(Pulsatilla chinensis)の根であるハクトウオウを配合することを特徴とする脂肪吸収抑制剤。 A fat absorption inhibitor characterized by containing a bald beetle that is the root of a plant of the family Ranunculaceae, Pulsatilla chinensis . キンポウゲ科の植物ヒロハオキナグサ(Pulsatilla chinensis)の根であるハクトウオウを配合することを特徴とするリパーゼ阻害剤。 A lipase inhibitor comprising a bald beetle that is the root of a plant of the family Ranunculaceae, Pulsatilla chinensis . キンポウゲ科の植物ヒロハオキナグサ(Pulsatilla chinensis)の根であるハクトウオウを配合することを特徴とする肥満の予防または改善剤。 A preventive or ameliorating agent for obesity characterized by containing bald eagle, which is the root of the plant of the family Ranunculaceae, Pulsatilla chinensis . キンポウゲ科の植物ヒロハオキナグサ(Pulsatilla chinensis)の根であるハクトウオウを配合することを特徴とする血清高トリグリセリド血症の予防または改善剤。 A preventive or ameliorating agent for serum hypertriglyceridemia , comprising a bald beetle that is a root of a plant of the family Ranunculaceae (Pulsatilla chinensis) .
JP2004365631A 2004-12-17 2004-12-17 Fat absorption inhibitor Expired - Fee Related JP4892833B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004365631A JP4892833B2 (en) 2004-12-17 2004-12-17 Fat absorption inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004365631A JP4892833B2 (en) 2004-12-17 2004-12-17 Fat absorption inhibitor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011094624A Division JP5382055B2 (en) 2011-04-21 2011-04-21 Fat absorption inhibitor
JP2011094625A Division JP2011178796A (en) 2011-04-21 2011-04-21 Fat absorption depressant

Publications (2)

Publication Number Publication Date
JP2006169181A JP2006169181A (en) 2006-06-29
JP4892833B2 true JP4892833B2 (en) 2012-03-07

Family

ID=36670313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004365631A Expired - Fee Related JP4892833B2 (en) 2004-12-17 2004-12-17 Fat absorption inhibitor

Country Status (1)

Country Link
JP (1) JP4892833B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150065021A (en) * 2013-12-04 2015-06-12 원광대학교산학협력단 Composition comprising Pulsatilla koreana Nakai extract or active ingredient isolated from the same for preventing or treating obesity

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008037764A (en) * 2006-08-02 2008-02-21 Shiseido Co Ltd Sebum secretion inhibitor and skin external preparation for ameliorating acne
JP2021132543A (en) 2020-02-25 2021-09-13 株式会社ファーマフーズ Fat absorption inhibitor, food product, defatted sesame, and method for inhibiting obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940000234B1 (en) * 1989-09-04 1994-01-12 김송배 Novel pharmaceutical composition having an antitumor activity and a process for preparation thereof
KR100312622B1 (en) * 1998-11-03 2002-02-28 김송배 Stabilized anticancer composition mainly composed of herbal medicine and its manufacturing method
JP2002020261A (en) * 2000-07-06 2002-01-23 Pola Chem Ind Inc Agent for restructuring corium collagen fiber bundle and composition containing the same
KR100568607B1 (en) * 2002-07-22 2006-04-07 김송배 Use of hederagenin 3-O-?-L-rhamnopyranosyl1?2-[?-D-glucopyranosyl1?4]-?-L-arabinopyranoside or extracts from Pulsatillae radix containing the same as therapeutic agents for solid tumors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150065021A (en) * 2013-12-04 2015-06-12 원광대학교산학협력단 Composition comprising Pulsatilla koreana Nakai extract or active ingredient isolated from the same for preventing or treating obesity
KR101629797B1 (en) * 2013-12-04 2016-06-16 원광대학교 산학협력단 Composition comprising Pulsatilla koreana Nakai extract or active ingredient isolated from the same for preventing or treating obesity

Also Published As

Publication number Publication date
JP2006169181A (en) 2006-06-29

Similar Documents

Publication Publication Date Title
Upton Stinging nettles leaf (Urtica dioica L.): Extraordinary vegetable medicine
US5945106A (en) Montoxic extract of Larrea tridentata and method of making the same
US10471114B2 (en) Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome
US6261607B1 (en) Composition for promoting prostate health containing selenium and herbal extracts
JP3966689B2 (en) Lipase inhibitor
JP4002654B2 (en) Blood lipid improving agent, cyclic AMP phosphodiesterase inhibitor, obesity preventive / eliminating agent, food and beverage, and skin external preparation
JP5609834B2 (en) Lipase inhibitor
KR101672274B1 (en) Compositions comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity
FR3080989A1 (en) LIQUID COMPOSITION COMPRISING AN EXTRACT OF CASSIS LEAVES AND CONCENTRATED APPLE JUICE
Jalili et al. An overview of therapeutic potentials of Taraxacum officinale (dandelion): A traditionally valuable herb with a reach historical background
JP4892833B2 (en) Fat absorption inhibitor
KR20140137289A (en) Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease
KR101160088B1 (en) Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover
JP2006104182A (en) Composition for reducing body fat
JP4982946B2 (en) Lipase inhibitor
JP5382055B2 (en) Fat absorption inhibitor
Delbò Assessment report on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix
JP2011148837A (en) Lipase inhibitor
KR101896815B1 (en) Health functional food composition for anorexia improvement and pharmaceutical composition for preventing or treating anorexia improvement
JP4907280B2 (en) Lipase inhibitor
KR100895500B1 (en) Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient
JP2011178796A (en) Fat absorption depressant
JP4706174B2 (en) α-Glucosidase inhibitor
JP4547892B2 (en) α-Glucosidase inhibitor
KR20110040174A (en) A composition comprising an extract of portulaca oleracea for preventing or treating diabetes, diabetic complications

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071206

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090605

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111122

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111205

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees